Related Experiment Video
Updated: May 4, 2026
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Towards a unified model of RAF inhibitor resistance
11Department of Medicine, 2Human Oncology and Pathogenesis Program, and 3Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Abstract:
ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in patients with BRAF-mutant melanoma. Analysis of tumor samples collected at the time of disease progression indicates that alterations within the extracellular signal-regulated kinase (ERK) pathway that result in reactivation of ERK signaling are present in most patients. Mutations in the phosphoinositide 3-kinase/AKT pathway that enhance the adaptive response to RAF inhibitors also contribute to RAF inhibitor resistance in a subset of patients.
Insights
BRAF-mutant melanoma patients initially respond to RAF inhibitors, but resistance develops. Reactivation of the extracellular signal-regulated kinase (ERK) pathway and phosphoinositide 3-kinase/AKT pathway mutations drive this resistance, limiting treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF-mutant melanoma is a significant health concern.
- ATP-competitive RAF inhibitors show initial efficacy but often temporary responses.
- Understanding resistance mechanisms is crucial for improving melanoma treatment.
Purpose of the Study:
- To investigate the molecular mechanisms underlying resistance to ATP-competitive RAF inhibitors in BRAF-mutant melanoma.
- To identify key signaling pathways involved in treatment failure.
Main Methods:
- Analysis of tumor samples from patients with BRAF-mutant melanoma at the time of disease progression.
- Molecular profiling to identify genetic alterations in signaling pathways.
Main Results:
- Most patients exhibited alterations in the extracellular signal-regulated kinase (ERK) pathway, leading to ERK signaling reactivation.
- A subset of patients showed mutations in the phosphoinositide 3-kinase/AKT pathway, contributing to adaptive resistance.
Conclusions:
- Reactivation of ERK signaling is a primary mechanism of resistance to RAF inhibitors in BRAF-mutant melanoma.
- Phosphoinositide 3-kinase/AKT pathway mutations also play a role in resistance, necessitating combination therapies or alternative treatment strategies.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
